(NASDAQ: ONC) Beone Medicines's forecast annual revenue growth rate of 17.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Beone Medicines's revenue in 2025 is $4,562,002,000.On average, 4 Wall Street analysts forecast ONC's revenue for 2025 to be $7,483,831,619,315, with the lowest ONC revenue forecast at $7,449,382,516,296, and the highest ONC revenue forecast at $7,533,768,801,037. On average, 5 Wall Street analysts forecast ONC's revenue for 2026 to be $9,069,541,682,330, with the lowest ONC revenue forecast at $8,708,253,782,155, and the highest ONC revenue forecast at $9,289,311,339,918.
In 2027, ONC is forecast to generate $10,655,479,174,650 in revenue, with the lowest revenue forecast at $9,899,468,405,728 and the highest revenue forecast at $11,533,669,543,376.